Therapeutic Indications

Aztreonam is indicated for:

Chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis (CF)

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

Aztreonam is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Respiratory (Inhalation) - 225 mg in 3 divided doses daily

Bone and joint infections, skin and soft tissue infections

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 2-8 g in 2-4 divided doses daily

Treatment 2: Intramuscular - 2-8 g in 2-4 divided doses daily

Septicaemia

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 2-8 g in 2-4 divided doses daily

Treatment 2: Intramuscular - 2-8 g in 2-4 divided doses daily

Intra-abdominal infections

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 2-8 g in 2-4 divided doses daily

Treatment 2: Intramuscular - 2-8 g in 2-4 divided doses daily

Lower respiratory tract infections in cystic fibrosis

Irrespective of gender only Adults (18 years old or older)

Lower respiratory tract infections: including pneumonia, bronchitis and lung infections in patients with cystic fibrosis.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 6-8 g in 3-4 divided doses daily

Gonorrhea

Irrespective of gender only Adults (18 years old or older)

Acute uncomplicated urogenital or anorectal infections due to beta-lactamase producing or non-producing strains of N. gonorrhoeae.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intramuscular - 1 g once

Bacterial meningitis

Irrespective of gender only Adults (18 years old or older)

Meningitis caused by Haemophilus influenzae or Neisseria meningitidis. Since aztreonam provides only Gram negative cover, it should not be given alone as initial blind therapy, but may be used with an antibiotic active against Gram positive organisms until the results of sensitivity tests are known.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 2-8 g in 2-4 divided doses daily

Treatment 2: Intramuscular - 2-8 g in 2-4 divided doses daily

Gynaecological infections

Women only, only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 2-8 g in 2-4 divided doses daily

Treatment 2: Intramuscular - 2-8 g in 2-4 divided doses daily

Bone and joint infections, skin and soft tissue infections

Irrespective of gender only Minors (0 - 18 years old)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 120-200 mg/kg in 3-4 divided doses daily

Treatment 2: Intramuscular - 120-200 mg/kg in 3-4 divided doses daily

Septicaemia

Irrespective of gender only Minors (0 - 18 years old)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 120-200 mg/kg in 3-4 divided doses daily

Treatment 2: Intramuscular - 120-200 mg/kg in 3-4 divided doses daily

Intra-abdominal infections

Irrespective of gender only Minors (0 - 18 years old)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 120-200 mg/kg in 3-4 divided doses daily

Treatment 2: Intramuscular - 120-200 mg/kg in 3-4 divided doses daily

Lower respiratory tract infections in cystic fibrosis

Irrespective of gender only Minors (0 - 18 years old)

Lower respiratory tract infections: including pneumonia, bronchitis and lung infections in patients with cystic fibrosis.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 120-200 mg/kg in 3-4 divided doses daily

Treatment 2: Intramuscular - 120-200 mg/kg in 3-4 divided doses daily

Urinary tract infection

Irrespective of gender only Minors (0 - 18 years old)

Urinary tract infections: including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to pathogens resistant to the aminoglycosides, cephalosporins or penicillins.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 120-200 mg/kg in 3-4 divided doses daily

Treatment 2: Intramuscular - 120-200 mg/kg in 3-4 divided doses daily

Bacterial meningitis

Irrespective of gender only Minors (0 - 18 years old)

Meningitis caused by Haemophilus influenzae or Neisseria meningitidis. Since aztreonam provides only Gram negative cover, it should not be given alone as initial blind therapy, but may be used with an antibiotic active against Gram positive organisms until the results of sensitivity tests are known.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 120-200 mg/kg in 3-4 divided doses daily

Treatment 2: Intramuscular - 120-200 mg/kg in 3-4 divided doses daily

Urinary tract infection

Irrespective of gender only Adolescents (12 years - 18 years old) Adults (18 years old or older)

Urinary tract infections: including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to pathogens resistant to the aminoglycosides, cephalosporins or penicillins.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1.5-3 g in 2-3 divided doses daily

Treatment 2: Intramuscular - 1.5-3 g in 2-3 divided doses daily

Contraindications

Active ingredient Aztreonam is contraindicated in the following cases:

Hypersensitivity to aztreonam

No gender/age discrimination